Keryx Biopharmaceuticals (NASDAQ: KERX) to Present at JP Morgan's 30th Annual Healthcare Conference
 small.png)
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging small-cap biopharma company that is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
On Wednesday, the company announced that its Company's Chief Executive Officer, Ron Bentsur, will be presenting at JP Morgan's 30th Annual Healthcare Conference, being held January 9th-12th in San Francisco, California. Mr. Bentsur's presentation is scheduled to take place on Thursday, January 12, 2012 at 10:00 a.m. PT (1:00pm ET).
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be also available after the conclusion of the live presentation.
Read more at The Business Journals.
ProActive Capital Indexes
See ProActive's Disclaimer